Paul Burton, Moderna CMO

Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments

Mod­er­na’s new CMO Paul Bur­ton spoke to re­porters Thurs­day morn­ing, at­tempt­ing to de­fend his com­pa­ny’s vac­cine against ques­tions around heart-re­lat­ed risks that ap­pear to be crop­ping up in very rare in­stances among younger men.

The me­dia push comes as the Mod­er­na vac­cine has proven to be over­whelm­ing­ly safe in more than 155 mil­lion in­di­vid­u­als. But coun­tries like Fin­land, Swe­den, Nor­way and Den­mark have lim­it­ed use of the Mod­er­na vac­cine to men over the age of 30, as it found the younger men who re­ceived the vac­cine, known as Spike­vax, had a slight­ly high­er risk of de­vel­op­ing my­ocardi­tis when com­pared to oth­er vac­cines.

“Some health au­thor­i­ties have not­ed a slight­ly in­creased risk of my­ocardi­tis when com­pared to the Pfiz­er-BioN­Tech vac­cine and that equates to about 10 ad­di­tion­al cas­es in every 100,000 peo­ple who would be vac­ci­nat­ed,” Bur­ton said.

But he al­so not­ed that when my­ocardi­tis does ap­pear, typ­i­cal­ly af­ter the sec­ond dose with males, for the most part it re­solves on its own. He al­so said the rea­son why men get my­ocardi­tis while women do not may be linked to testos­terone.

Mod­er­na did not re­spond to a ques­tion about fur­ther de­tails for why the FDA has pushed back its re­view of the com­pa­ny’s vac­cine for younger pop­u­la­tions. The com­pa­ny pre­vi­ous­ly said the FDA needs ad­di­tion­al time to com­plete its as­sess­ment for the vac­cine among ado­les­cents 12 to 17 years old be­cause the agency wants to “eval­u­ate re­cent in­ter­na­tion­al analy­ses of the risk of my­ocardi­tis af­ter vac­ci­na­tion,” Mod­er­na said. The re­view could take un­til Jan­u­ary.

EMA en­dors­es first 2 mAb treat­ments from Roche and Cell­tri­on

As Covid-19 cas­es con­tin­ue to in­crease across Eu­rope, the Eu­ro­pean Med­i­cines Agency on Thurs­day signed off on two new mon­o­clon­al an­ti­body treat­ments sub­mit­ted by Roche (Re­gen­eron de­vel­oped the mAb) and Cell­tri­on.

Al­though the US has au­tho­rized and dis­trib­utes three mAb treat­ments to states (de­vel­oped by Re­gen­eron, Eli Lil­ly and GSK/Vir), these are the first two OKs from the EMA for mAb treat­ments.

EMA’s hu­man med­i­cines com­mit­tee rec­om­mend­ed au­tho­riz­ing Roche and Re­gen­eron’s mAb treat­ment, known in the EU as Ron­apreve, for treat­ing Covid-19 in those who are 12 years of age and old­er, weigh at least 40 kilo­grams (88 pounds), and who are at in­creased risk of their dis­ease be­com­ing se­vere but do not yet re­quire sup­ple­men­tal oxy­gen.

Ron­apreve al­so won a nod as a pro­phy­lac­tic in the same pop­u­la­tion.

With re­gard to Cell­tri­on’s Regkirona, the com­mit­tee rec­om­mend­ed au­tho­riz­ing the treat­ment for adults with Covid-19 who do not re­quire sup­ple­men­tal oxy­gen and who are al­so at in­creased risk of their dis­ease be­com­ing se­vere.

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

The field of cell and gene therapies (C&GTs) has seen a renaissance, with first generation commercial therapies such as Kymriah, Yescarta, and Luxturna laying the groundwork for an incoming wave of potentially transformative C&GTs that aim to address diverse disease areas. With this renaissance comes several potential opportunities, of which we discuss three predictions below.

Allogenic Natural Killer (NK) Cells have the potential to displace current Cell Therapies in oncology if proven durable.

Despite being early in development, Allogenic NKs are proving to be an attractive new treatment paradigm in oncology. The question of durability of response with allogenic therapies is still an unknown. Fate Therapeutics’ recent phase 1 data for FT516 showed relatively quicker relapses vs already approved autologous CAR-Ts. However, other manufacturers, like Allogene for their allogenic CAR-T therapy ALLO-501A, are exploring novel lymphodepletion approaches to improve persistence of allogenic cells. Nevertheless, allogenic NKs demonstrate a strong value proposition relative to their T cell counterparts due to comparable response rates (so far) combined with the added advantage of a significantly safer AE profile. Specifically, little to no risk of graft versus host disease (GvHD), cytotoxic release syndrome (CRS), and neurotoxicity (NT) have been seen so far with allogenic NK cells (Fig. 1). In addition, being able to harness an allogenic cell source gives way to operational advantages as “off-the-shelf” products provide improved turnaround time (TAT), scalability, and potentially reduced cost. NKs are currently in development for a variety of overlapping hematological indications with chimeric antigen receptor T cells (CAR-Ts) today, and the question remains to what extent they will disrupt the current cell therapy landscape. Click for more details.

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The sto­ry of sotro­vimab; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

For those of you who attended #JPM22 in any shape or form, we hope you had a fruitful time. Regardless of how you spent the past hectic week, may your weekend be just what you need it to be.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

A patient in Alaska receiving an antibody infusion to prevent Covid hospitalizations in September. All but one of these treatments has been rendered useless by Omicron (Rick Bowmer/AP Images)

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

Exactly a decade before a novel coronavirus broke out in Wuhan, Davide Corti — a newly-minted immunologist with frameless glasses and a quick laugh — walked into a cramped lab on the top floor of an office building two hours outside Zurich. He had only enough money for two technicians and the ceiling was so low in parts that short stature was a job requirement, but Corti believed it’d be enough to test an idea he thought could change medicine.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

A $3B+ peak sales win? Pfiz­er thinks so, as FDA of­fers a tardy green light to its JAK1 drug abroc­i­tinib

Back in the fall of 2020, newly crowned Pfizer chief Albert Bourla confidently put their JAK1 inhibitor abrocitinib at the top of the list of blockbuster drugs in the late-stage pipeline with a $3 billion-plus peak sales estimate.

Since then it’s been subjected to serious criticism for the safety warnings associated with the class, held back by a cautious FDA and questioned when researchers rolled out a top-line boast that their heavyweight contender had beaten the champ in the field of atopic dermatitis — Dupixent — in a head-to-head study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf, FDA commissioner nominee (Graeme Sloan/Sipa USA/Sipa via AP Images)

Rob Califf ad­vances as Biden's FDA nom­i­nee, with a close com­mit­tee vote

Rob Califf’s second confirmation process as FDA commissioner is already much more difficult than his near unanimous confirmation under the Obama administration.

The Senate Health Committee on Thursday voted 13-8 in favor of advancing Califf’s nomination to a full Senate vote. Several Democrats voted against Califf, including Sen. Bernie Sanders and Sen. Maggie Hassan. Several other Democrats who aren’t on the committee, like West Virginia’s Joe Manchin and Ed Markey of Massachusetts, also said Thursday that they would not vote for Califf. Markey, Hassan and Manchin all previously expressed reservations about the prospect of Janet Woodcock as an FDA commissioner nominee too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (World Economic Forum/Ciaran McCrickard)

Bio­gen vows to fight CM­S' draft cov­er­age de­ci­sion for Aduhelm be­fore April fi­nal­iza­tion

Biogen executives made clear in an investor call Thursday they are not preparing to run a new CMS-approved clinical trial for their controversial Alzheimer’s drug anytime soon.

As requested in a draft national coverage decision from CMS earlier this week, Biogen and other anti-amyloid drugs will need to show “a meaningful improvement in health outcomes” for Alzheimer’s patients in a randomized, placebo-controlled trial to get paid for their drugs, rather than just the reduction in amyloid plaques that won Aduhelm its accelerated approval in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

CRO own­er pleads guilty to ob­struct­ing FDA in­ves­ti­ga­tion in­to fal­si­fied clin­i­cal tri­al da­ta

The co-owner of a Florida-based clinical research site pleaded guilty to lying to an FDA investigator during a 2017 inspection, revealing that she falsely portrayed part of a GlaxoSmithKline pediatric asthma study as legitimate, when in fact she knew that certain data had been falsified, the Department of Justice said Wednesday.

Three other employees — Yvelice Villaman Bencosme, Lisett Raventos and Maytee Lledo — previously pleaded guilty and were sentenced in connection with falsifying data associated with the trial at the CRO Unlimited Medical Research.

Susan Galbraith, AstraZeneca EVP, Oncology R&D

Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

After establishing itself in the front ranks of cancer drug developers and marketers, AstraZeneca is putting its scientific shoulder — and a significant amount of cash — behind the wheel of a brash new upstart in the biotech world.

The pharma giant trumpeted news this morning that it is handing over $75 million upfront to ally itself with Scorpion Therapeutics, one of those biotechs that was newly birthed by some top scientific, venture and executive talent and bequeathed with a fortune by way of a bankroll to advance an only hazily explained drug platform. And they are still very much in the discovery and preclinical phase.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

‘Skin­ny la­bels’ on gener­ics can save pa­tients mon­ey, re­search shows, but re­cent court de­ci­sions cloud fu­ture

New research shows how generic drug companies can successfully market a limited number of approved indications for a brand name drug, prior to coming to market for all of the indications. But several recent court decisions have created a layer of uncertainty around these so-called “skinny” labels.

While courts have generally allowed generic manufacturers to use their statutorily permitted skinny-label approvals, last summer, a federal circuit court found that Teva Pharmaceuticals was liable for inducing prescribers and patients to infringe GlaxoSmithKline’s patents through advertising and marketing practices that suggested Teva’s generic, with its skinny label, could be employed for the patented uses.